Drug profile · INN
dicyclomine hydrochloride
DICYCLOMINE HYDROCHLORIDE
dicyclomine hydrochloride (DICYCLOMINE HYDROCHLORIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — dicyclomine hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
dicyclomine hydrochloride (DICYCLOMINE HYDROCHLORIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dicyclomine hydrochloride?
dicyclomine hydrochloride (DICYCLOMINE HYDROCHLORIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dicyclomine hydrochloride?
DICYCLOMINE HYDROCHLORIDE is a marketed brand name for dicyclomine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dicyclomine hydrochloride?
dicyclomine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.